Beta BionicsvsJohnson & Johnson

BBNX and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

BBNX

Beta Bionics, Inc.

$13.06

Value $710M

-8.86%
BBNX's page

Beta Bionics (BBNX) has a market value of $710M and Johnson & Johnson (JNJ) $644B. Over the last year, with dividends, BBNX moved -51.8% and JNJ +36.5%. Dividend yield: BBNX none, JNJ 1.97%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BBNX$710M

    JNJ$644B

    JNJ is 907 times BBNX

  • Revenue, 12 months

    BBNX$127M

    JNJ$99.3B

    JNJ is 781 times BBNX

  • Net income, 12 months

    BBNX-$83M

    JNJ$16.1B

  • Operating margin

    BBNX-72.8%

    JNJ–

  • ROIC

    BBNX-24.2%

    JNJ12.4%

    36.6 points apart

  • P/E

    BBNX–

    JNJ40.0

  • Dividend yield

    BBNX0.0%

    JNJ2.0%

    2.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BBNX-51.8%

JNJ+36.5%

50100150DecFebAprJunAugOct
Returns by period
PeriodBBNXWith dividendsJNJWith dividends
1 year since November 18, 2025-51.8%Price -51.8%+36.5%Price +33.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BBNXBeta BionicsJNJJohnson & Johnson

Valuation

BBNXJNJ
Valuation
Price$13.06$267.36
Market value$710M$644B
Enterprise value (EV)$470M$672B
P/E–40.0
P/E, 5-year median–21.9
P/B1.87.9
EV/EBIT–37.9
Free cash flow yield–3.2%

Results and growth

BBNXJNJ
Results and growth
Revenue, 12 months$127M$99.3B
Net income, 12 months-$83M$16.1B
Free cash flow, 12 months-$66M$20.6B
Earnings per share, 12 months-$1.83$6.59
Revenue growth, year on year53.9%6.1%
Revenue growth a year, past+189.1%over 2 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

BBNXJNJ
Margins and returns on capital
Gross margin58.6%67.6%
Operating margin-72.8%–
Net margin-65.3%16.2%
ROIC-24.2%12.4%
ROE-27.5%19.7%

Balance sheet

BBNXJNJ
Balance sheet
Cash$240M$17.2B
Total debt$6.2M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

BBNXJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BBNX or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Beta Bionics or Johnson & Johnson?

By market value, Johnson & Johnson ($644B) is about 907.4 times Beta Bionics ($710M), at today's prices.

How did BBNX and JNJ stock do over the last 1 years?

Since November 18, 2025, BBNX's price moved -51.8% and JNJ's +33.5%. With dividends: BBNX -51.8% (-51.8% a year), JNJ +36.5% (+36.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, BBNX or JNJ?

The dividend yield at today's price is none for Beta Bionics and 1.97% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Beta Bionics or Johnson & Johnson?

Over the last twelve months, the net margin was -65.3% for Beta Bionics and 16.2% for Johnson & Johnson, and the operating margin -72.8% and –. Revenue was $127M and $99.3B.

Which is the better investment, Beta Bionics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.